Moderna stock price is skyrocketing on mRNA cancer vaccine trial news: Here’s what’s happening
Summary
Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck’s immunotherapy medication Keytruda, met initial goals in a late-stage trial. The ongoing mRNA cancer vaccine study involves 1,137 patients with high-risk melanoma that has been surgically remove
Visit the original source for the full article








